A Psychobiological Follow-up Study of Transition from Prodrome to Early Psychosis

从前驱症状到早期精神病转变的心理生物学随访研究

基本信息

批准号：
10011832
负责人：
Huijun Li
金额：
$ 58.91万
依托单位：
BETH ISRAEL DEACONESS MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-09-21 至 2022-09-14
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10011832
关键词：
Address Adolescent and Young Adult Age Age of Onset American Asia Asians Australia Biological Biological Assay Biological Markers Biological Process Brain China Clinical Clinical Trials Cognitive Collaborations Community Health Education Data Data Collection Diffuse Diffusion Magnetic Resonance Imaging Early Intervention Europe Event-Related Potentials Evolution Family member Florida Follow-Up Studies Foundations Functional Magnetic Resonance Imaging Goals Grant Hospitals Individual Institutes Intervention Joints Literature Longevity Longitudinal Studies Magnetic Resonance Imaging Massachusetts Measures Medial Memory Mental Health Movement Myelin National Institute of Mental Health Nature Neurocognition Neurocognitive North America Outcome Parahippocampal Gyrus Participant Patients Pharmaceutical Preparations Phase Prefrontal Cortex Preventive Intervention Process Psychotic Disorders Research Research Personnel Research Training Rest Risk Risk Factors Role Schizophrenia Singapore Site Social Functioning Solid Structure Surveys Symptoms Taiwan Technology Testing Time Training Training and Education United States National Institutes of Health Universities Verbal Learning Water Work World Health Organization base biopsychosocial clinical biomarkers disability follow up assessment follow-up gray matter high risk high risk population improved low and middle-income countries medical schools mental health center neocortical nervous system disorder neuroinflammation novel predictive marker preference processing speed programs progression marker psychobiologic psychosocial response social social stigma virtual white matter

项目摘要

7. Project Summary/Abstract: There is a worldwide movement in the early intervention for adolescents and young adults appearing to develop early signs of psychosis or described as at clinical high risk (CHR) for psychosis, led mainly by researchers in Australia, Europe, and North America. Within the Asian Network for Early Psychosis, Taiwan and Singapore have started to address the CHR population. To our knowledge, we are the first research group carrying out CHR studies in a low-middle income country in Asia. Since 2012, supported by NIMH/Fogarty 1R21MH093294-01A1 and an NIMH R01 MH101052-01, we have worked closely with the Shanghai Mental Health Center (SMHC), to develop a CHR research program in Shanghai, China. The completed R21 and on-going R01 projects aim at identification of the risk factors for CHR conversion over approximately one year. In our current proposal, in response to NIH FOA PAR-14-332, Global Brain and Nervous System Disorders Research across the Lifespan (R01), we will continue to enhance research capacity building at SMHC, and collaboratively carry out an extensive follow-up study of clinical outcomes such as conversion to psychosis and level of disability, and we will evaluate the evolution of biomarkers such as event related potentials, resting state functional magnetic resonance imaging (MRI), white matter as assessed by diffusion tensor imaging MRI, and neurocognition. We will follow-up 300 well characterized CHR and Healthy Control (HC) participants between the ages of 15-45 for two more follow-up assessments. The longitudinal nature of the project is novel in China and worldwide as this will be the first study to comprehensively examine biopsychosocial parameters predictive of psychosis conversion and illness progression for up to 6 years, including two new follow-ups of the biomarkers (4 assessments including baseline). Moreover, unlike many studies in the West, virtually 100% of the participants are psychotropically naïve when they enter the study, and the assessments are done at one site (SMHC), reducing confounds associated with medications and multiple sites. Our goal is to work collaboratively with researchers at the SMHC to establish a sustainable CHR longitudinal program of research in China and to lay a solid foundation for CHR early intervention.This project aims to: 1). Develop predictors for conversion to psychosis, 2). Investigate clinical and biomarker progression in CHR, 3). Demonstrate an association between clinical features, biological measures and disability in CHR, and 4). Explore the feasibility of early intervention with CHR subjects. Capacity building and research training will be conducted during and beyond the proposed project to facilitate sustainable research at SMHC.

7. 项目概要/摘要：世界范围内有一场针对青少年和年轻人的早期干预运动，似乎出现精神病的早期症状或被描述为精神病的临床高风险 (CHR)，主要由澳大利亚、欧洲和北美的研究人员，来自台湾的亚洲早期精神病网络。据我们所知，新加坡和新加坡已开始针对 CHR 人群进行研究，我们是第一个研究小组。自 2012 年起，在 NIMH/Fogarty 的支持下，在亚洲的一个中低收入国家开展 CHR 研究。 1R21MH093294-01A1 和 NIMH R01 MH101052-01，我们与上海市精神卫生局密切合作中心 (SMHC)，在中国上海开展 CHR 研究项目已完成的 R21 和正在进行中。 R01 项目旨在识别大约一年内 CHR 转换的风险因素。当前提案，响应 NIH FOA PAR-14-332，全球大脑和神经系统疾病研究在整个生命周期（R01）中，我们将继续加强 SMHC 的研究能力建设，并且合作对临床结果进行广泛的后续研究，例如转变为精神病和残疾程度，我们将评估生物标志物的演变，例如事件相关电位、休息状态功能磁共振成像 (MRI)，通过扩散张量成像 MRI 评估白质，我们将跟踪 300 名特征明确的 CHR 和健康控制 (HC) 参与者。年龄在 15-45 岁之间，进行两次后续评估该项目的纵向性质是新颖的。在中国和世界各地，因为这将是第一项全面检查生物心理社会参数的研究预测精神病转变和疾病进展长达 6 年，包括两项新的随访此外，与西方的许多研究不同，几乎 100%。的参与者在进入研究时在精神治疗上是幼稚的，并且评估是在一次完成的站点（SMHC），减少与药物和多个站点相关的混乱。与 SMHC 的研究人员合作，建立可持续的 CHR 纵向研究计划为CHR早期干预奠定坚实的基础。该项目旨在： 1). 转化为精神病，2) 研究 CHR 的临床和生物标志物进展，3)。 CHR 的临床特征、生物学指标和残疾之间的关联，以及 4) 探索可行性。将在期间和期间开展对 CHR 受试者的早期干预的能力建设和研究培训。超出了促进 SMHC 可持续研究的拟议项目。